Elutia’s (ELUT) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Elutia (NASDAQ:ELUT) in a research note released on Friday,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Elutia Stock Down 7.0 %

NASDAQ ELUT opened at $3.56 on Friday. The stock has a market cap of $121.25 million, a PE ratio of -1.36 and a beta of 0.76. Elutia has a fifty-two week low of $1.39 and a fifty-two week high of $5.24. The business has a 50 day moving average price of $3.73 and a two-hundred day moving average price of $3.69.

Hedge Funds Weigh In On Elutia

A number of institutional investors and hedge funds have recently bought and sold shares of ELUT. Arcus Capital Partners LLC purchased a new position in shares of Elutia during the 2nd quarter valued at approximately $50,000. Renaissance Technologies LLC boosted its stake in shares of Elutia by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock valued at $266,000 after buying an additional 18,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Elutia by 50.3% during the 3rd quarter. Geode Capital Management LLC now owns 188,408 shares of the company’s stock valued at $718,000 after buying an additional 63,047 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in shares of Elutia by 9.8% during the 3rd quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock valued at $3,263,000 after buying an additional 76,450 shares during the last quarter. Finally, AIGH Capital Management LLC boosted its stake in shares of Elutia by 288.8% during the 2nd quarter. AIGH Capital Management LLC now owns 1,697,316 shares of the company’s stock valued at $8,419,000 after buying an additional 1,260,750 shares during the last quarter. Hedge funds and other institutional investors own 74.03% of the company’s stock.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.